1、 刘苗苗,南岩东,陈艳丽,等.血清肿瘤标志物和自身抗体与肺癌患者临床病理特征的相关性研究[J]. 中华肺部疾病杂志,2018,11(2):176-181. 刘苗苗,南岩东,陈艳丽,等.血清肿瘤标志物和自身抗体与肺癌患者临床病理特征的相关性研究[J]. 中华肺部疾病杂志,2018,11(2):176-181.
2、 SUD A, THOMSEN H, SUNDQUIST K, et al. Risk of second cancer in hodgkin lymphoma survivors and influence of family history[J]. Clin Oncol,2017, 35(14):1584-1590. SUD A, THOMSEN H, SUNDQUIST K, et al. Risk of second cancer in hodgkin lymphoma survivors and influence of family history[J]. Clin Oncol,2017, 35(14):1584-1590.
3、 DONG L, HU S Y, ZHANG Q, et al. Dynamic changes of human papillomavirus genotype distribution in Shanxi cervical cancer screening cohort in 10 years[J]. Chin J Epidemiol,2017, 38(1):20-25. DONG L, HU S Y, ZHANG Q, et al. Dynamic changes of human papillomavirus genotype distribution in Shanxi cervical cancer screening cohort in 10 years[J]. Chin J Epidemiol,2017, 38(1):20-25.
4、 MAYADEV J, LIM J, DURBIN B, et al. Smoking decreases survival in locally advanced cervical cancer treated with radiation[J]. Am J Clin Oncol,2018,41(3):295-301. MAYADEV J, LIM J, DURBIN B, et al. Smoking decreases survival in locally advanced cervical cancer treated with radiation[J]. Am J Clin Oncol,2018,41(3):295-301.
5、 BERNSTEIN J L, WECARE Study Collaborative Group, CONCANNON P. ATM, radiation, and the risk of second primary breast cancer[J]. Int J Radiat Biol,2017,93(10):1121-1127. BERNSTEIN J L, WECARE Study Collaborative Group, CONCANNON P. ATM, radiation, and the risk of second primary breast cancer[J]. Int J Radiat Biol,2017,93(10):1121-1127.
6、 PAPPAS K, XU J, ZAIRIS S, et al. p53 maintains vaseline expression of multiple tumor suppressor genes[J]. Mol Cancer Res,2017,15(8):1051-1062. PAPPAS K, XU J, ZAIRIS S, et al. p53 maintains vaseline expression of multiple tumor suppressor genes[J]. Mol Cancer Res,2017,15(8):1051-1062.
7、 CHATURVEDI A K, ENGELS E A, GILBERT E S, et al. Second cancers among 104 760 survivors of cervical cancer: Evaluation of long-term risk[J]. J Natl Cancer Inst,2017,99(21):1634-1643. CHATURVEDI A K, ENGELS E A, GILBERT E S, et al. Second cancers among 104 760 survivors of cervical cancer: Evaluation of long-term risk[J]. J Natl Cancer Inst,2017,99(21):1634-1643.
8、 魏晓玲, 洪英极, 王林硕, 等. 潮汕地区原发性双侧乳腺癌癌灶间相关性分析[J]. 汕头大学医学院学报,2018,31(4):234-238. 魏晓玲, 洪英极, 王林硕, 等. 潮汕地区原发性双侧乳腺癌癌灶间相关性分析[J]. 汕头大学医学院学报,2018,31(4):234-238.
9、 宋诗平, 赵越, 王春玉, 等. 雌激素受体在甲状腺癌中作用的研究进展[J]. 第三军医大学学报,2017,29(5),489-494. 宋诗平, 赵越, 王春玉, 等. 雌激素受体在甲状腺癌中作用的研究进展[J]. 第三军医大学学报,2017,29(5),489-494.
10、 罗伟平, 何雩霏, 钟礼信, 等. 2008—2019年广州某综合医院肿瘤病例分析[J]. 广州医药, 2020, 51(4): 114-118. 罗伟平, 何雩霏, 钟礼信, 等. 2008—2019年广州某综合医院肿瘤病例分析[J]. 广州医药, 2020, 51(4): 114-118.
11、 魏星, 刘向阳.同时性多原发肺腺癌31例临床分析与治疗体会[J]. 中国医刊,2017,52(5):86-90. 魏星, 刘向阳.同时性多原发肺腺癌31例临床分析与治疗体会[J]. 中国医刊,2017,52(5):86-90.
12、 DUANMU Y Y, WANG R P. Professor Wang experience in the treatment of multiple primary cancer[J]. Guid J Tradit Chin Med Pharmacol,2018,24(9):53-54. DUANMU Y Y, WANG R P. Professor Wang experience in the treatment of multiple primary cancer[J]. Guid J Tradit Chin Med Pharmacol,2018,24(9):53-54.
13、 PAREKH J D, KUKRETY S, THANDRA A, et al. Multiple primary malignant neoplasms in an elderly patient[J]. Cureus,2018,10(3):2384. PAREKH J D, KUKRETY S, THANDRA A, et al. Multiple primary malignant neoplasms in an elderly patient[J]. Cureus,2018,10(3):2384.
14、 NEMES A, TODOR N, NAGY V. Clinicopathological characteristics of patients with multiple primary neoplasms-a retrospective analysis[J]. J BUON,2018,23(6):1846-1854. NEMES A, TODOR N, NAGY V. Clinicopathological characteristics of patients with multiple primary neoplasms-a retrospective analysis[J]. J BUON,2018,23(6):1846-1854.
15、 AL-HUSSEINI M J, MOHAMED H H, SAAD A M, et al. Risk and survival of chronic myeloid leukemia after breast cancer: A population-based study[J]. Curr Probl Cancer,2019,43(3):213-221. AL-HUSSEINI M J, MOHAMED H H, SAAD A M, et al. Risk and survival of chronic myeloid leukemia after breast cancer: A population-based study[J]. Curr Probl Cancer,2019,43(3):213-221.
16、 ZHAI C Y, CAI Y L, LOU F, et al. Multiple primary malignant tumors-A clinical analysis of 15,321 patients with malignancies at a single center in China[J]. J Cancer,2018,9(16):2795-2801. ZHAI C Y, CAI Y L, LOU F, et al. Multiple primary malignant tumors-A clinical analysis of 15,321 patients with malignancies at a single center in China[J]. J Cancer,2018,9(16):2795-2801.
17、 SIMEONOVSKI V, BRESHKOVSKA H, DUMA S, et al. Hydroxyurea associated cutaneous lesions: A case report[J]. Open Access Maced J Med Sci,2018,6(8):1458-1461. SIMEONOVSKI V, BRESHKOVSKA H, DUMA S, et al. Hydroxyurea associated cutaneous lesions: A case report[J]. Open Access Maced J Med Sci,2018,6(8):1458-1461.
18、 WANG H, HOU J, ZHANG G, et al. Clinical characteristics and prognostic analysis of multiple primary malignant neoplasms in patients with lung cancer[J]. Cancer Gene Ther,2019,26(11-12),419-426. WANG H, HOU J, ZHANG G, et al. Clinical characteristics and prognostic analysis of multiple primary malignant neoplasms in patients with lung cancer[J]. Cancer Gene Ther,2019,26(11-12),419-426.
19、 SINGH J, THOTA N, SINGH S, et al. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel:prevalence of BRCA1/2 and non-BRCA mutations[J]. Breast Cancer Res Treat,2018,170(1):189-196. SINGH J, THOTA N, SINGH S, et al. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel:prevalence of BRCA1/2 and non-BRCA mutations[J]. Breast Cancer Res Treat,2018,170(1):189-196.
20、 YAMAUCHI H, TAKEI J. Management of hereditary breast and ovarian cancer[J]. Int J Clin Oncol,2018,23(1):45-51. YAMAUCHI H, TAKEI J. Management of hereditary breast and ovarian cancer[J]. Int J Clin Oncol,2018,23(1):45-51.
